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57 ABSTRACT 
Biocompatible microcapsules useful for transplanting for 
eign material into an animal body, and the method of their 
production, are described, wherein the microcapsules con 
tain an outermost layer of water Soluble non-ionic polymers 
Such as PEO to create resistance to cell adhesion on the 
Surface of the microcapsules. 
10 Claims, 5 Drawing Sheets 
PERMEABILITY OF BILAYERED MICROSPHERES WITH 
DFFERENT PEO GRAFTS IN OUTERMOST LAYER. 
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This is a continuation of co-pending application Ser. No. 
07/598,880, filed on Oct. 15, 1990. 
BACKGROUND 
Microencapsulation of materials for transport to and/or 
growth within an animal is an area of research currently 
attracting much interest. The use of microcapsules provides 
the potential for Such medically important procedures as 
treatment of insulin-dependent diabetes mellitus (IDDM) in 
humans through transplantation of insulin-producing cells, 
and timed release or long term delivery of drugs to an 
animal. 
The microencapsulation membrane plays a critical role in 
the treatment of IDDM by microencapsulated islet cells, as 
well as treatment of other diseases with other encapsulated 
material. Not only must it prohibit proteins of the immune 
System from entering the capsule, but it must also interact 
with the host tissues in a biocompatible way. In this Sense, 
biocompatibility means that the membrane will not initiate 
an inflammatory response and that it will not Support cell 
adhesion and Stimulate overgrowth. If Overgrowth occurs, 
the oxygen and nutrient Supply to the islets will be limited 
and they will die. The area of biocompatibility of 
microcapsules, however, has received relatively little atten 
tion. 
The principle of immunoisolation is to Surround the cells 
with a biocompatible Semipermeable membrane, which 
allows free diffusion of nutrients, messenger compounds, 
cell wastes, and cell products, while isolating the cells from 
the host’s immune system. The cells may be individual or 
clumped in tissue. Messenger compounds and cell products 
include glucose, Ca", and insulin. 
Two methods for the immunoisolation of cells exists: 
hollow-fiber devices and microencapsulation. One form of 
hollow-fiber devices are an artificial capillary System con 
sisting of hollow fibers to which cells are seeded on their 
exteriors, and which are enclosed in a rigid chamber that is 
connected to the recipient as a vascular shunt. Early devices 
using insulin producing cells reversed diabetes for limited 
periods with high doses of heparin. Sun et al. (1977) 
Diabetes, 26:1136-39. But even with heparin, blood clot 
formation was a major problem. To reduce the formation of 
clots, which Suffocated the cells, Altman et al. have Seeded 
Amicon fibers successfully, with nearly half of the animal 
recipients having normal blood glucose levels for over a 
year. Altman et al. (1986) Diabetes, 35.625-33. However, 
the Amicon fibers are fragile and they have a limited Surface 
area available for diffusion. AU-shaped ultrafiltration design 
developed by Reach et al. can solve the diffusion problem, 
but this design still suffers from the fragility of the Amicon 
fibers and from the formation of blood clots at the junction 
with the vascular system. Reach et al. (1984) Diabetes, 
33:752-61. 
The transplantation of microencapsulated cells or tissue 
can overcome the hollow-fiber associated problems of dif 
fusion limitations and vascular complications, originally, 
Sun and Lim demonstrated the technique by encapsulating 
rat pancreatic islet cells into a membrane composed of layers 
of alginate, polylysine, and polyethyleneimine. Sun and Lim 
(1980) Science, 210:908-910. The microcapsules were 
injected into chemically induced diabetic rats. These micro 
capsules corrected the diabetic State for only 2 to 3 weeks. 
Gradually the technique improved. A large improvement 











polylysine-alginate, which is Stronger and has controllable 
permeability parameters. Goosen et al. (1985) Biotech. and 
Bioengin.., XXVII:146-50. King and Goosen et al. devel 
oped methods for decreasing the Viscosity of the gel inside 
So that the tissue or cells are in a more natural environment 
(1987) Biotechnology Progress, 3:231-240. A further 
advance was making the microcapsules in a more uniform, 
Smooth, Spherical shape which improved their Strength. 
Walter et al. Poster Group H. 
With these changes, Sun et al. have transplanted rat islets 
of Langerhans into chemically induced diabetic rats which 
have reversed the diabetic state for up to 780 days, Sun 
(1987) Trans Am Soc. Artif. Intern Organs, 
XXXIII: 787-790. In vitro studies have shown that antibod 
ies from Type 1 human diabetic patients were not able to 
Suppress encapsulated cells, Darquy and Reach (1985) 
Diabetologia, 28:776-80. Therefore, it seems that microen 
capsulation can protect cells from antibodies. However, 
there are Still Several Serious problems in regards to bio 
compatibility. Sun has reported finding fibroblast-like cells 
on the external Surfaces of intact microcapsules. Sun had 
transplanted the microencapsulated rat islet cells into dia 
betic rats. Sun (1987) Trans Am. Soc. Artif. Intern Organs 
XXXIII:787-790. In his articles, Sun has specifically rec 
ognized the need to improve the biocompatibility of the 
microcapsules. Id. at 810. 
Other published studies have also seen this inflammatory 
response to transplanted microencapsulated cells. In another 
study of microencapsulated rat islet cells, O'Shea and Sun 
found that the microcapsules that they transplanted into 
chemically induced diabetic mice had cell overgrowth in the 
range of 0-10 layers of cells. The overgrowing cells 
included fibroblasts, macrophage-like cells and neutrophils. 
There was also collagen around the capsules. O'Shea and 
Sun (1986) Diabetes, 35:943–946. Again, O'Shea and Sun 
expressly recognized that the biocompatibility of the micro 
capsules must be improved. Id. at 946. 
The inflammatory response is not limited to transplants of 
islet cells. Wong and Chang have reported recovering 
clumped microcapsules of rat hepatocytes after they were 
transplanted into mice with liver failure. They found no 
viable cells within the clumped microcapsules, which were 
recovered only Seven days after transplantation. Wong and 
Chang (1988) Biomat., Art. Cells, Art. Org., 16 (4):731-739. 
The cells probably died because they were cut off from 
nutrients when the cells grew over the Semi-permeable 
membrane. 
Current formulations for microcapsules result in algin 
polycationic polymer-algin composites. The exterior of 
these membranes are negatively charged, due to the algin, 
and may have positive charges due to exposed polycation; as 
Such they Support protein adsorption and cell attachment. In 
general, these microcapsules become overgrown with fibro 
blasts and other cells. This overgrowth has many negative 
effects, including impairment of the functioning of the 
microcapsule by blocking permeability, and induction of 
immune response by the host animal. 
The microencapsulation technique that had previously 
met with the most success is that of O'Shea and Sun (1986) 
Diabetes, 35.943-946. Their method uses the strong inter 
action between large multicharged molecules, one cationic 
and one anionic, to form a very thin, Stable, Spherical 
membrane Shell that resists the diffusion of large proteins, 
such as antibodies, while allowing the diffusion of smaller 
proteins, Such as insulin. 
Such a membrane is obtained by Suspending cells to be 
encapsulated in a Solution of algin, a polyanionic polysac 
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charide that is obtained from kelp. Very small droplets of this 
Solution are formed, approximately 0.1–1.0 mm in diameter 
depending on the Size of the material to be encapsulated, and 
these droplets are gelled on contact with a fairly highly 
concentrated solution of calcium chloride, 0.2-1.6% CaCl. 
The calcium cations, in this high concentration, Serve to 
reversibly crosslink the anionic polysaccharide chains, 
forming the gel. 
To obtain a membrane that would be stable at physiologic 
concentrations of calcium, the negatively charged microcap 
Sule is placed in a Solution of a positively charged polymer, 
for example, polylysine. The opposite charges interact, 
leading to very Strong adsorption of the polylysine, resulting 
in a stable, Strongly crosslinked Surface. Similarly, an outer 
layer of algin is added, yielding an algin-polylysine-algin 
composite trilayer membrane. 
The Solid inner core of gelled algin is liquefied by placing 
the microcapsules in a Solution of Sodium citrate to chelate 
the gelling calcium. At physiologic calcium levels, the core 
remains liquid and the algin, if of low enough molecular 
weight, diffuses out of the core. The result is a spherical shell 
of algin-polylysine-algin Surrounding the microencapsu 
lated cells. 
It is predictable that Such an algin-polylysine-algin micro 
capsule will not resist tissue overgrowth. The exterior Sur 
face is highly charged, with both positive and negative 
charges, and would thus be expected to adsorb significant 
amounts of protein and to Support cell adhesion. Andrade et 
al. (1986) Adv. Polymer Sci., 79:1–63. Experimentally, 
tissue overgrowth has been observed to be the point of 
failure of the microencapsulation therapy. O'Shea and Sun 
(1986). 
Poly(ethyleneoxide) (PEO) has been used in numerous 
instances to decrease cellular attachment. For instance, PEO 
coatings on PVC tubes have been reported as significantly 
reducing platelet adhesion in Vitro and preventing adhesion 
and thrombus formation in 72 day PVC tube implants in 
vivo. (Y. Mori et al., Trans. Am. Soc. Artif. Intern. Organs 
28:459 (1982)). Volume restriction and osmotic repulsion 
effects were credited with producing the low adsorption of 
blood constituents. (Id.). Later research concluded that there 
were micro flows of water induced by the cilia-like move 
ments of hydrated PEO chains which prevent plasma pro 
teins from absorbing onto the surface of coated PVC tubes. 
(S. Nagaoka and A. Nakao, Biomaterials 11:119 (1990)). 
In addition to PVC tube coatings, others have reported 
that Segmented polyurethanes containing PEO as the Soft 
Segment, when cast as films or coatings, Show reduced 
platelet retention in vitro. (E. W. Merrill et al., Trans. Am. 
Soc. Artif. Intern. Organs 28:482 (1982)). PEG 
polyurethane coatings on disks made of Pellethane were 
shown to cause the disks to have reduced cellular adhesion 
for up to 3 months when implanted into the peritoneal 
cavities of mice. (S. K. Hunter et al., Trans. Am. Soc. Artif. 
Intern. Organs 29:250 (1983)). Block co-polymers consist 
ing of poly(N-acetylethyleneimine) and PEO, when coated 
on Solids Such as glass beads or Silica, were found to increase 
the homeo-compatibility of the Solids by decreasing adsorp 
tion of hydrophilic macromolecules. (C. Maechling-Strasser 
et al., J. of Biomedical Materials Research 23:1385 (1989)). 
Long term canine vascular implants of Biomer coated 
with polymers have been tested for adsorption of proteins. 
(C. Nojiri et al. Trans. Am. So. Artif. Intern. Organs, 35:357 
(1989)). The polymer coatings found to have “excellent 
non-thrombogenic performance” were: 1) Heparin immobi 











block copolymer composed of 2-hydroxyethyl methacrylate 
(HEMA) and styrene. (Id.). 
Low density polyethylene (a hydrophobic polymer 
Surface) coated with a block copolymer containing water 
insoluble components (such as polypropylene oxide or poly 
butylene oxide) and PEO components (water soluble 
components) was shown to have protein resistant properties. 
(J. H. Lee et al., J. of Biomedical Materials Research, 23:351 
(1989)). The Surface was created by a simple coating process 
where the hydrophobic components of the polymer adsorbed 
on the hydrophobic surface of the polyethylene from an 
aqueous Solution, the PEO chains were then at least partially 
extended into the aqueous Solution creating a protein resis 
tant Surface. (Id.). 
Processes used to achieve PEO Surfaces other than a 
Simple coating process have been described: block 
co-polymerization (Y. Mori Supra), incorporation into poly 
urethanes (E. W. Merrill supra); and direct attachment of 
PEO molecules to the cyanuric chloride activated Surface of 
a poly(ethylene terephthalate) film. (W. R. Gombotz et al., J. 
of Applied Polymer Science 37.91 (1989)). 
Most of the foregoing uses of PEO have been on concave 
or flat Surfaces, they have not been on Small conveX Surfaces 
Such as are found with microcapsules. Due to the fact that 
the non-ionic water Soluble polymerS face outward from the 
microcapsule, it could not be predicted from the prior art that 
PEO and other non-ionic water soluble polymers could form 
a Sufficient barrier to protect microcapsular Surfaces. 
Likewise, the chemistry was not known for attaching Suffi 
cient quantities of water Soluble non-ionic polymers to the 
outer Surfaces of microcapsules to create this barrier. 
SUMMARY OF THE INVENTION 
This invention for the first time demonstrates the use of 
water soluble non-ionic polymers such as PEO to create 
resistance to cell adhesion on the Surface of microcapsules. 
This invention provides a method for transplanting for 
eign material into an animal body in a biocompatible man 
ner. This is accomplished by providing microcapsules, bio 
compatible with the recipient animal, capable of 
encapsulating the foreign material to be transplanted into 
that animal. The normally charged outer layer of the micro 
capsules is covered by water Soluble non-ionic polymers 
such as poly(ethylene oxide) (PEO) which act to shield the 
charge. These polymers are grafted to the polycationic 
polymers, Such as poly-L-lysine (PLL) molecules used as at 
least one of the layers of the microcapsule, Such that they 
create a non-ionic barrier between the Outer layer of the 
microcapsule (made of essentially either polycationic 
polymers, Such as PLL, or polyanionic polymers, Such as 
alginate) and the recipient animal. The microcapsules then 
appear, from the outside, to have water-like Surface 
properties, thus reducing the driving force for protein 
adsorption. Further, the Surface, at the macromolecular 
level, is in a high degree of motion, further reducing protein 
adsorption and cell attachment. 
This invention further provides microcapsules, and a 
method for their production, in which the Surface is more 
resistant to cell adhesion. As a result, overgrowth of the 
microcapsules by cells Such as fibroblasts and macrophages 
is Severely decreased or eliminated. Cells contained within 
the microcapsules are able to continue to receive nutrients 
and Signal molecules, and produce whatever is their desired 
product. Any product present in the microcapsules, Such as 
insulin produced by islet cells, can continue to diffuse out of 




This invention also provides microcapsules, and a method 
for their production, which will not appreciably Stimulate 
immune response or cytokine release by the recipient ani 
mal. Thus, these microcapsules can be transplanted to a 
recipient animal and function there with minimal interfer 
ence from that animal's immune System. 
This invention provides microcapsules with variable lev 
els of permeability. This is accomplished by using varying 
numbers of layers to make the microcapsules, with an 
increased number of layerS decreasing the pore size. Thus, 
the microcapsules can be created to meet a particular need 
for large or Small pores and the resulting level of perme 
ability. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGURES 
FIG. 1 shows the effect of the molecular weight of the 
water Soluble non-ionic polymer on permeability of micro 
Spheres formed using grafted material. 
FIG. 2 shows the effect of the number of layers used to 
form the microSpheres on permeability. 
FIG. 3 is a Schematic of the activation reaction using 
carbodiimidazole. 
FIG. 4 is a Schematic of the activation reaction using 
sulfonyl chlorides, where R is as shown. 
FIG. 5 is a Schematic of the activation reaction using 
chlorocarbonates. 
FIG. 6 shows cell counts obtained from peritoneal lavage 
after implantation of micro capsule S. CDI 
(carbodiimidazole), PFBS (pentafluorobenzenesulfonyl 
chloride), trifyl (trifyl chloride), and chlorocarb 
(chlorocarbonate) were used to activate PEO (poly(ethylene 
oxide)) for grafting to poly(1-lysine) according to this inven 
tion. FIG. 6a represents results when PEO of molecular 
weight around 5 k.d was used; FIG. 6b used PEO of 10 k.d.; 
and FIG. 6c shows results from PEO of 18.5 kd. Numbers 
of cells are shown on the left of each graft. e--7 stands for 
107, so that 1.00 e--7 is 1.00x107 cells. 
DETAILED DESCRIPTION 
According to this invention, microcapsules are assembled 
from various layers of a polyanionic polysaccharide, Such as 
alginate, and a polycationic polymer, Such as poly(l-lysine) 
(PLL). The polycationic polymer need not be a polypeptide. 
The Outer polycation layer is composed of the polycationic 
polymer grafted to a water Soluble non-ionic polymer, Such 
as poly(ethylene oxide) (PEO) to form a graft copolymer, 
such as PLL-g-PEO. The layers are alternated such that the 
oppositely charged polymers, for example algin and PLL, 
aggregate to form coacervates, Such as algin-PLL--algin. 
This creates an ionically crosslinked membrane. 
However, PLL is known to promote cell adhesion, so at 
least the outermost layer of PLL or other polycation in this 
invention is composed of the graft copolymer. PEO, as well 
as other water Soluble non-ionic polymers, have been shown 
to reduce cell adhesion when used to modify a Surface. Lee 
et al. (1989) J. Biomed. Materials Res. 23:351–368. This 
dual-character graft copolymer interacts with the polyan 
ionic layer, Such as algin, to form a Stable membrane through 
interactions between the polycationic backbone, Such as 
PLL, and the polyanionic layer. The long arms of the 
non-ionic polymer, Such as PEO, however, Serve to obscure 
the charged layerS from the tissues, thereby improving the 
biocompatibility. They create a very hydrophilic and 












The water Soluble non-ionic polymers are covalently 
attached to the polycationic polymers and point in all 
directions including outward from the microcapsule. 
1. Water Soluble Non-ionic Polymers 
Water soluble non-ionic polymers with molecular weights 
of between 2000 and 50,000 are suitable for this procedure. 
PEO of approximately 10,000 m.w.. is the most preferred. 
Molecules with molecular weights lower than around 2000 
do not adequately shield the microcapsule, while those 
greater than around 50,000 create steric limitations on the 
microcapsules. In addition, molecules with higher molecular 
weights cause an increase in the Swelling of the 
microcapsules, interfering with the interactions between the 
polyanionic polysaccharides and the polycationic polypep 
tides. As a result, the polyanionic polysaccharide layer does 
not adhere as well, and the integrity of the microcapsules can 
be threatened. 
Additionally, the size of the water soluble non-ionic 
polymers affects permeability of the microcapsule. The 
larger molecules create greater permeability. This feature 
can be manipulated to obtain the optimal degree of perme 
ability for the particular use of the microcapsules. For 
microcapsules encapsulating insulin-producing islet cells, 
the optimal permeability is created with PEO around 10,000 
m.w.. in a pentalayer membrane (see below and FIGS. 1 and 
2). 
2. Activation 
Procedures used to graft the water Soluble non-ionic 
polymers to the polycationic polymers include but are not 
limited to use of carbodiimidazole, Sulfonyl chlorides, or 
chlorocarbonates to activate the water Soluble non-ionic 
polymers. These reagents are used to activate free hydroxyl 
groups for coupling to polycationic polypeptides. 
Other chemistries for linking water soluble non-ionic 
polymers to polycationic polymers, known by those skilled 
in the art, can also be used. 
a. Carbodiimidazole 
To X millimoles of PEO or other water Soluble nonionic 
polymer in at least a 1% Solution in anhydrous acetone or 
other anhydrous organic Solvent is added at least 1X, pref 
erably 5X millimoles of carbodiimidazole. Larger quantities 
of carbodiimidazole can be used but will not increase the 
rate or amount of the activation. The reaction mixture is 
Stirred at a temperature above the freezing point and below 
the melting point of the mixture, preferably at room tem 
perature of around 22 C., for at least /2 hour, preferably 
around 2 hours. The product is then washed at least twice 
with methanol with HCl or other strong acid to convert the 
organic base to the conjugate, and finally with pure metha 
nol. Washes can be formed by solubilization of the reaction 
product in the wash Solvent, followed by reprecipitation and 
Sedimentation, for example by Settling at 1 g or in a 
centrifuge at higher acceleration, preferably 1000 rcf for 10 
minutes. The final wash is checked to be free of any residual 
pyridine or other base by UV spectrophotometry. The pel 
leted product is then recovered. Other purification Schemes 
known by those skilled in the art can also be used. The 
product can then be lyophilized and stored. FIG. 1 shows the 
reaction Scheme. 
b. Sulfonyl chlorides 
To create good leaving group characteristics in Sulfonyl 
chlorides, two main approaches are used: the first is fluori 
nation and the Second is nitration. Thus a number of organic 
chlorides can be used to produce end-activated water Soluble 
non-ionic polymer chains with a varying degree of effec 
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tiveness. By way of example, the order of reactivity of 
coupling for Toluene sulfonyl chloride (Tosyl chloride): 
Trifluoroethanesulfonyl chloride (Tresyl chloride): Trifluo 
romethanesulfonyl chloride (Trifyl chloride) is 1:100:4000. 
AS reactivity increases, Stability decreases. Therefore an 
organic chloride with intermediate traits is preferred. Other 
Sulfonyl chlorides Such as dansyl, dipSyl, and diabSyl chlo 
ride can also be used, but with lower effectiveness. Other 
problems Such as difficulty in removal of unreacted dansyl 
functions by nucleophiles and tendency for diabsyl chloride 
to undergo further Secondary reactions leading to a signifi 
cant red shift make these sulfonyl chlorides less Suitable. 
These may be overcome, for example, by employing higher 
levels of the activating agent and Subsequently purifying the 
products of the primary reaction from the products of the 
Secondary competing reactions. 
Another compound, Pentafluorobenzenesulfonyl chloride 
(PFBS), however, is as reactive as tresyl chloride, is cheaper, 
and is chromophoric, thus allowing an easy quantification of 
the extent of the reaction. Thus PFBS is a preferred reagent 
in this group. 
Sulfonyl chlorides are readily available from a number of 
commercial chemical SupplierS Such as Aldrich and Fluka. 
To X millimoles of PEO or other nonionic water Soluble 
polymer in at least a 1% Solution in anhydrous methylene 
chloride or other anhydrous organic Solvent at a temperature 
above the freezing point and below the melting point of the 
mixture, preferably 4 C., is added at least 1X, preferably 5X 
millimoles of Sulfonyl chloride (larger quantities can be used 
but will not increase the rate or amount of the activation) and 
approximately twice as much pyridine, triethylamine, or 
other organic aprotic base, as Sulfonyl chloride. The reaction 
mixture is stirred for at least 10 minutes, preferably around 
2 hours. The product is then washed at least twice with 
methanol with HCl or other strong acid to convert the 
organic base to the conjugate, and finally with pure metha 
nol. Washes can be formed by solubilization of the reaction 
product in the wash Solvent, followed by reprecipitation and 
Sedimentation, for example by Settling at 1 g or in a 
centrifuge at higher acceleration, preferably 1000 rcf for 10 
minutes. The final wash is checked to be free of any residual 
pyridine or other base by UV spectrophotometry. The pel 
leted product is then recovered. Other purification Schemes 
known by those skilled in the art can also be used. The 
product can then be lyophilized and stored. FIG.2 shows the 
reaction Scheme. 
c. Chlorocarbonates 
Chlorocarbonates such as P-nitrophenyl chlorocarbonate 
(Fluka), 2,4,5 trichlorophenyl chlorocarbonate, and 
N-hydroxySuccinamide chlorocarbonate are examples that 
react efficiently for activation of hydroxyl containing com 
pounds Such as the water Soluble non-ionic polymers used in 
this invention. Other chlorocarbonates known by those 
skilled in the art can also be used. 
To X millimoles of PEO or other water Soluble nonionic 
polymer in at least a 1% Solution in anhydrous methylene 
chloride or other anhydrous organic Solvent at a temperature 
above the freezing point and below the melting point of the 
mixture, preferably 4 C., is added at least 1X, preferably 5X 
millimoles of chlorocarbonate (larger quantities can be used 
but will not increase the rate or amount of the activation) and 
approximately twice as much pyridine, triethyl amine or 
other organic aprotic base. The reaction mixture is stirred at 
a temperature above the freezing point and below the 
melting point of the mixture, preferably at room temperature 











2 hours. The product is then washed at least twice with 
methanol with HCl or other strong acid to convert the 
organic base to the conjugate, and finally with pure metha 
nol. Washes can be performed by solubilization of the 
reaction product in the wash Solvent, followed by reprecipi 
tation and Sedimentation, for example by Settling at 1 g or in 
a centrifuge at higher acceleration, preferably 1000 rcf for 
10 minutes. The final wash is checked to be free of any 
residual pyridine or other base by UV spectrophotometry. 
The pelleted product is then recovered. Other purification 
Schemes known by those skilled in the art can also be used. 
The product can then be lyophilized and stored. FIG. 3 
shows the reaction Schemes. 
3. Polycationic Polymers 
Polycationic polymers are selected for their ability to 
form Strong membrane coacervates with algin or other 
polyanions. Such polycationic polymers include polypep 
tides and non-polypeptides. Polypeptides include, but are 
not limited to, polylysine and polyornithine. Non 
polypeptides include, but are not limited to, polyethylene 
imine and polyallylamine. The molecular weight of these 
polycationic polymerS is important but not critical, and 
optimal values are determined by their ability to form Strong 
membrane coacervates. Very low molecular weight polyca 
tion polymers generally form membranes that are weak and 
very high polycation polymers generally form membrane 
coacervates that are very thin. Typical values for the molecu 
lar weight of the polycation polymers are between about 
10,000 and 75,000. A preferred substrate is poly(1-lysine), 
which has been previously used in its ungrafted form as a 
component of microcapsule membranes. 
4. Coupling 
Activated water Soluble non-ionic polymers are next 
coupled to the polycationic polymers. The polymers are 
mixed into a solution of the activated PEO or other water 
Soluble nonionic polymer, agitated and allowed to react for 
a period of at least /3 day. The pH of the solution is 
maintained around 9t2. The coupling reaction is Stopped by 
quenching through the addition of an amine or a thiol Such 
as mercaptoethanol. Quenching is allowed to proceed for at 
least /2 hour, preferably 10 hours. 
If desired, ultrafiltration, dialysis, or Soxlet eXtraction can 
be used to separate the unreacted PEO from the PLL-g-PEO. 
In addition, the extent of reaction can be estimated using a 
Spectrophotometric titration of amine groups where, for 
example, the amine groups are reacted with 2,4,6- 
trinitrobenzene Sulfonic acid, forming a product that absorbs 
at 440 nm. The extent of reaction can also be determined by 
estimating the relative amounts of copolymers using 
H-NMR. 
5. Formation of Microcapsules 
Formation of the microcapsule is by Standard techniques. 
O'Shea and Sun (1986). Material to be encapsulated is 
Suspended in a Solution of polyanionic polysaccharides, 
preferably algin, at a concentration that will allow the cells 
to receive adequate nutrients as well as Signal molecules and 
produce the desired product(s) once the microcapsules are 
formed. A preferred concentration is 1x10 to 1x10 cells/ 
ml. Droplets of this Solution are dropped into a Solution of 
isotonic calcium chloride in saline, preferably 0.2 to 1.6% 
CaCl2.H2O. Passing the Solution under pressure through a 
fine-gauge needle or orifice in a sterile air Stream is one 
method of producing the droplets. They are then washed in 
isotonic Saline or buffer and placed in a Solution of the 
polycationic polymer, preferably PLL. Alternatively, they 
can be placed in a Solution of water Soluble non-ionic 
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polymer-grafted-polycationic polymer, as described herein. 
The polycationic polymer or water Soluble non-ionic 
polymer-grafted-polycationic polymer Solution should be 
approximately 0.03%–0.3%, preferably 0.1%. The droplets 
are allowed to react with the polymers for a period of time 
from 3–30 minutes, preferably 12 minutes. 
The microcapsules are removed from the polymer Solu 
tion by, for example, decanting the liquid. The 2-layer 
droplets are then washed with isotonic saline or buffer and 
may be coated with one or more layer of polyanionic 
polysaccharides, preferably another layer of algin. This is 
accomplished by reacting the bilayer droplets with a 
0.05–0.25% solution of polyanionic polysaccharide, prefer 
ably a 0.15% solution of algin, for a period of 3-30 minutes, 
preferably 8 minutes. 
Next, a layer of water Soluble non-ionic polymer-grafted 
polycationic polymer, preferably PEO-g-PLL, can be added 
to the microcapsule. This is performed by incubation of the 
microcapsules in a Solution of the grafted polymer at the 
Same concentration range, for the same period of time, as for 
the non-grafted polycationic polymers. Alternatively, the 
first layer of polycationic polymer may be replaced by water 
Soluble non-ionic polymer-grafted-polycationic polymer, 
such as PLL-g-PEO, and the second layer of this grafted 
polycationic polymer may be included or omitted. An outer 
layer of algin may or may not be added at the same 
concentration range, for the same period of time, as for the 
inner one. 
The number of layers used in each microcapsule can be 
used to determine Several parameters of interest for trans 
plantation. The prior art discloses use of microcapsules with 
3 layers, as described in O'Shea and Sun (1986). The 
number of layers can be increased by adding Subsequent 
alternating layers of polyanionic polysaccharides and poly 
cationic polypeptides. The polycationic polymers grafted to 
the water Soluble non-ionic polymers should at least be used 
as the last or next to last layer of the microcapsule, and must 
be at least the Outermost polycationic layer. 
Increasing the number of layerS decreases the permeabil 
ity of the microcapsules. Thus, permeability can be con 
trolled to Selectively allow diffusion across the microcapsule 
membrane. The addition of water soluble non-ionic poly 
mers to the polycationic polypeptide layer increases perme 
ability. Therefore, in order to eliminate the immune response 
of the host animal to cells encapsulated within these 
microcapsules, Such as Xenograft insulin producing islet 
cells, it is necessary to counter this permeability increase. A 
preferred method is to add an additional two layers to the 
Surface of the microcapsule. This brings the permeability 
back to the level found in 3-layer microcapsules described in 
the art which do not have the grafted water soluble non-ionic 
polymers. 
Additionally, increasing the number of layers of the 
microcapsule membrane increases the Strength and Stability 
of the microcapsules. However, this stability must be bal 
anced with the decrease in permeability caused by the 
increased layers. Thus, for use in encapsulating living cells 
that produce a desired product when transplanted to a host 
animal, a 5-layer microcapsule according to this invention is 
most preferred, whether made with both ungrafted and 
grafted polycation polymer or Solely with grafted polycation 
polymer. 
Microcapsules formed by the above procedures can be 
degelled at this step to remove exceSS gelled polyanionic 
polysaccharide immediately Surrounding the encapsulated 











and the microcapsules will function well without degelling. 
If degelling is desired, Standard procedures described in the 
art, Such as incubation in a Sodium citrate Solution can be 
employed. O'Shea and Sun (1986). 
6. Implantation of Microcapsules 
Microcapsules are Suspended in a Solution compatible for 
injection, Such as isotonic Saline, buffer or tissue culture 
medium. Microcapsules can be implanted in the peritoneal 
cavity of a host animal by Standard techniques. In addition, 
they can be implanted in any bodily location which provides 
Sufficient circulation of the products of the encapsulated 
material to allow metabolic functioning of those products. 
For example, with microcapsules containing insulin 
producing islet cells, intramuscular locations will allow 
Sufficient exposure to the blood circulatory System to allow 
effective use of the insulin. 
EXAMPLE 1. 
Activation of PEO Using Carbodiimidazole 
Three Separate reactions were performed, each using PEO 
of a different molecular weight class. 1 millimole each of 
PEO-5K (5000 d), PEO-10K (10,000 d) and PEO-18.5K 
(18,500 d) were used. The PEO-5K material was 
monomethoxy end terminated; as Such these polymerS had 
only one terminal, activatable hydroxyl group, thus mini 
mizing croSS-linking reactions in the coupling Step. 50% 
Solutions of these polymers were made up in anhydrous 
acetone which had been dried overnight over 4 A molecular 
sieves, and 5 millimoles of carbodiimidazole (CDI) was 
added to them. The reaction mixes were stirred at room 
temperature for 2 hrs. The reaction mixes were then washed 
four times with 60 ml of anhydrous acetone by chilling the 
Solution to 0 C. to precipitate, decanting, adding fresh 
solvent, and warming to 22 C. to redissolve. The product 
was then lyophilized and Stored. 
EXAMPLE 2 
Activation of PEO Using Sulfonyl Chlorides 
Three Separate reactions were performed, each using PEO 
of a different molecular weight class. 1 millimole each of 
PEO-5K, PEO-1OK AND PEO-18.5K were used. The PEO 
5K material was monomethoxy end terminated; as Such 
these polymerS had only one terminal, activatable hydroxyl 
group, thus minimizing cross-linking reactions in the cou 
pling Step. 50% weight/volume Solutions of these polymers 
were made up in anhydrous acetone which had been dried 
overnight over 4 A molecular sieves. The solutions were 
cooled to 4°C. and 5 millimoles of trifyl chloride or PFBS 
was added to these solutions along with 10 millimoles of 
pyridine. The reaction mix was stirred mechanically at room 
temperature for 2 hrs., at the end of which it was washed 
twice with 60 ml each of methanol containing 0.2 ml 
concentrated HCl, three times with 60 ml each of methanol 
containing 50 ul of HCl, and finally with pure methanol. The 
washes were done by solubilization at 40 C. and precipi 
tation at 4 C. followed by centrifugation at 1000 rcf. The 
final wash was checked to be free of any residual pyridine 
by ultraViolet spectroscopy. The product was lyophilized and 
stored at 4 C. 
EXAMPLE 3 
Activation of PEO Using P-Nitrophenyl 
Chlorocarbonate 
Three Separate reactions were performed, each using PEO 
of a different molecular weight class. 1 millimole each of 
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PEO-5K, PEO-1OK AND PEO-18.5K were used. The PEO 
5K material was monomethoxy end terminated; as Such 
these polymerS had only one terminal, activatable hydroxyl 
group, thus minimizing cross-linking reactions in the cou 
pling Step. 50%. Solutions of these polymers were made up 
in acetone which had been dried overnight over 4 A molecu 
lar sieves. The solutions were then cooled to 4 C. and 5 
millimoles each of pyridine and triethylamine and 5 milli 
moles of p-nitrophenyl chlorocarbonate (chlorocarb) were 
added. The mixtures were mechanically stirred and the 
reaction was allowed to proceed at room temperature for 2 
hrs. The reaction mix was then washed with cold acetone by 
adding 60 ml acetone at room temperature, cooling to 4 C. 
and centrifuging at 1000 rcf. The Washing was repeated once 
with acetone, then with a 5% acetic acid Solution in dioxane, 
and finally with methanol. The product was lyophilized and 
Stored. 
EXAMPLE 4 
Coupling Activated PEO to PLL 
20 mg of Poly(1-lysine) (PLL), molecular weight around 
17,000, was added to each 50% w/v Solution of the above 
activated polymers in 500 mM sodium borate buffer (pH 9) 
for 24 hours. The coupling reaction was stopped by quench 
ing using 0.36 mls of 14M Mercaptoethanol. The quenching 
was allowed to proceed for 10 hrs. 
The PEO-5K grafted to PLL and PEO-10K grafted to PLL 
formed clear Solutions. On the other hand, the PEO-18.5K 
grafted to PLL resulted in the formation of a very high 
molecular weight macromolecular network which had the 
consistency of a gel. Some parts of this gel were Soluble 
when diluted further but Some crosslinked portions remained 
insoluble. 
No attempt was made to separate the unreacted PEO from 
the PLL-g-PEC. The extent of reaction was estimated using 
Spectrophotometric titration of amine groups where the 
amine groups were reacted with 2,4,6-trinitrobenzene Sul 
fonic acid, forming a product that absorbs at 440 nm. 
EXAMPLE 5 
Relationship of Molecular Weight of the Water 
Soluble Non-Ionic Polymer to Permeability of 
Microspheres 
Use of grafted water Soluble non-ionic polymer to poly 
cationic polymer was found to affect the permeability of 
microcapsules. Microspheres were formed using PEO of 
varying molecular weights grafted to PLL as the Outer layer 
of a bilayer microsphere. The relationship of the size of the 
PEO used to the permeability of the microspheres was 
investigated. 
5 ml of algin solution was mixed with 100 ul of 'I 
labelled BSA for microsphere fabrication. Microspheres 
were formed following standard procedures. PLL-g-PEO 
having PEO chains of 5,000 d, 10,000 d, and 100,000 dwere 
used as the Outer layer. Control spheres were formed having 
ungrafted PLL as the outer layer. The microspheres were 
degelled with citrate. The degelled microSpheres were incu 
bated in 10 ml of citrate solution, which was sampled 
periodically for presence of 'I albumin that had secreted 
through the membrane. For this Sampling, 1 ml aliquots 
were counted in a gamma Scintillation counter. AS can be 
Seen in FIG. 1, permeability of the microSpheres increased 
in direct proportion to the size of the PEO component of the 
outer layer, with control spheres having ungrafted PLL being 











The effects of the presence of PEO on permeability could 
be reversed by increasing the number of layers used to form 
the microSpheres. Following Standard procedures, micro 
Spheres were formed having from two to four layers. AS can 
be seen in FIG. 2, microcapsules with PEO having 4 layers, 
where the inner polycationic layer was of ungrafted PLL, 
had the same permeability characteristics as the control 
microcapsules with 3 layers. Thus, varying the number of 
layerS altered the permeability characteristics of the 
microSpheres, and increasing the number of layers, using an 
inner layer of ungrafted PLL, returned the microcapsules to 




Approximately 0.5 ml of microcapsules were taken for 
each Sample. The Samples were washed 2 times in 10 ml 
each of isotonic Saline. After the final wash, each Sample of 
microcapsules was Suspended in 5 ml phosphate buffered 
saline (0.2M) pH 7.4 (PBS) and aliquoted into two equal 
parts. Duplicate animals, male Swiss Sprague-Dawley mice 
16–20 weeks old were used for each composition. Implants 
were made intraperitoneally (i.p.) using a 15 gauge needle. 
Animals were under ether anaesthesia. Microcapsules hav 
ing an outermost layer of PLL without the grafted water 
Soluble non-ionic polymers were used as controls. 
EXAMPLE 7 
Characterization of Implanted Microcapsules 
The implants were retrieved after one week using perito 
neal lavage. 5 ml of PBS, containing 10 U/ml heparin, was 
injected with pressure using a 22 gauge needle. The micro 
capsules were recovered using a transfer pipette through a 
Small hole made in the muscle flap over the peritoneal 
cavity. 
a) Cell Counts 
An immediate count of free cells recovered in the fluid in 
conjunction with the microcapsules was taken. These cells 
were incubated in polystyrene petri dishes for 2 hrs and then 
washed and fixed in 2% glutaraldehyde. Those cells adher 
ing to the petri dish were nearly uniformly found to be 
macrophages as revealed using a monoclonal antibody and 
Secondary fluorescence technique. The primary antibody 
was a rat anti-mouse macrophage antibody, clone #M1-70.15 
from Sera-lab obtained from Accurate Chemicals. The sec 
ondary antibody was a fluorescein conjugated goat anti-rat 
IgG polyclonal antibody obtained from Accurate Chemical. 
After antibody treatment, the samples were viewed by 
fluorescence microScopy. Some of the directly recovered 
peritoneal lavage fluid and Some control microcapsules 
which were covered with cells were also treated using the 
antibody fluorescence technique and were qualitatively 
judged to be about 50% macrophages. 
The results, shown in FIG. 4, show that the number of 
macrophages free floating in the peritoneal fluid was 
decreased by use of the products of this invention. This 
figure shows cell counts from the Samples. AS can be seen 
from this figure, use of the technology described in this 
invention lowers the number of macrophages and other cells 
induced by the presence of microcapsules in the peritoneal 
cavity. Evidence of Some foreign body giant cell formation 
was seen in all Samples that had cellular attachment. Varying 
levels of fluorescence was seen in Some macrophages which 
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might be an artifact of non-uniform Staining or may reflect 
different levels of cellular activation. A few cells which were 
not macrophages were also seen but their numbers were 
Small. 
The number of cells present in the peritoneal cavity was 
inversely correlated to the molecular weight of the grafted 
PEO. 
b) Photomicrographs 
A number of photomicrographs of the recovered micro 
capsules were taken. Photographs for each type of micro 
capsule were taken through a 40X phase contrast and a 400X 
Hoffman optics microScope. The lower magnification was 
used to reflect a broad cross-section of the microcapsules 
and the higher magnification was used to examine the 
Surface of the microcapsules and closely examine cell 
attachment. 
The control microcapsules, prepared from ungrafted poly 
(l-lysine), showed heavy cellular overgrowth as expected. A 
number of microSpheres were darkened by Overgrowth of 
cells. 
Microcapsules made according to the invention described 
herein showed little or no cell attachment. This can be seen 
by the clarity and transparency of the microcapsular Surfaces 
at the 40X magnification. Additionally, at 400X 
magnification, Surfaces of the microcapsules made using 
trifyl chloride and chlorocarbonate technology show clean 
Surfaces. 
We claim: 
1. A biocompatible microcapsule for transplantation into 
an animal comprising a membrane of more than one layer, 
with an outermost layer of hydrophilic non-ionic water 
Soluble polymers that have been covalently grafted to at 
least one of the layers, made of polyamine, polyamide or 
polyimine polycationic polymers able to form Strong mem 
brane coacerVates of the microcapsule membrane, wherein 
the hydrophilic polymer is of an effective molecular weight 
to Shield the microcapsules from cellular adhesion and 
provide an effective permeability to the microcapsules. 
2. The microcapsule of claim 1 wherein the non-ionic 
water Soluble polymers are Selected from the group consist 
ing of poly(ethylene oxide), poly(Vinyl pyrrolidone), poly 
(ethyl oxazoline), poly(Vinyl alcohol) and polysaccharides. 
3. A biocompatible microcapsule for transplantation into 
an animal comprising a membrane of more than one layer, 
with an outermost layer of dextran that has been covalently 
grafted to at least one of the layers, made of polyamine, 
polyamide or polyimine polycationic polymers able to form 
Strong membrane coacervates of the microcapsule mem 
brane wherein the dextran is of an effective molecular 
weight to Shield the microcapsules from cellular adhesion 








4. A biocompatible microcapsule for transplantation into 
an animal comprising a membrane of more than one layer, 
with an outermost layer of hyaluronic acid that has been 
covalently grafted to at least one of the layers, made of 
polyamine, polyamide or polyimine polycationic polymers 
able to form Strong membrane coacervates of the microcap 
Sule membrane, wherein the hyaluronic acid is of an effec 
tive molecular weight to Shield the microcapsules from 
cellular adhesion and provide an effective permeability to 
the microcapsules. 
5. The microcapsule of claim 2 wherein the water soluble 
non-ionic polymers are branched. 
6. The microcapsule of claim 2 wherein the water soluble 
non-ionic polymers are unbranched. 
7. The microcapsule of claim 1 wherein the polycationic 
polymers are Selected from the group consisting of 
polyly Sine, poly Ornithine, polyethylene imine, 
polyallylamine, and mixed copolymers thereof. 
8. Abiocompatible microcapsule for transplantations into 
an animal comprising a membrane of more than one layer, 
with an outermost layer of hydrophilic non-ionic water 
Soluble polymerS Selected from the group consisting of 
poly(ethylene oxide), poly(Vinyl pyrrolidone), poly(ethyl 
oxazoline), poly(Vinyl alcohol) and polysaccharides, or 
copolymers thereof, that have been covalently grafted to at 
least one of the other layers, made of polyamine, polyamide 
or polyimine polycationic polymerS Selected from the group 
consisting of polycationic polyamino acids, polyethylene 
imine and polyallylamine, or copolymers thereof, of the 
microcapsule membrane, wherein the hydrophilic polymer 
is of an effective molecular weight to Shield the microcap 
Sules from cellular adhesion and provide an effective per 
meability to the microcapsules. 
9. The microcapsule of claim 8 wherein the polycationic 
polyamino acids are Selected from the group consisting of 
polylysine, polyornithine, and copolymers thereof. 
10. An improved biocompatible microcapsule for trans 
plantation into an animal, having improved resistance to 
Overgrowth by cells, comprising a membrane of more than 
one layer, characterized in that the outermost layer com 
prises exposed non-ionic chains of a graft copolymer, the 
graft copolymer comprising at least one block of a polyca 
tionic polymer and at least one block of a hydrophilic, water 
Soluble, non-ionic polymer, and the graft copolymer adhered 
to the microcapsule predominantly by ionic bonds, wherein 
the hydrophilic polymer is of an effective molecular weight 
to Shield the microcapsules from cellular adhesion and 
provide an effective permeability to the microcapsules. 
